Long-term Drug Treatment for Obesity
Top Cited Papers
Open Access
- 1 January 2014
- journal article
- review article
- Published by American Medical Association (AMA) in JAMA
- Vol. 311 (1) , 74-86
Abstract
Obesity (body mass index [BMI, calculated as weight in kilograms divided by height in meters squared] ≥30) is highly prevalent in the United States; 36% (>78 million) of US adults are estimated to be obese.1 Almost all US health professionals in the United States treat patients with obesity and are well aware of its medical consequences.Keywords
This publication has 85 references indexed in Scilit:
- Managing obesity in primary care practice: an overview with perspective from the POWER-UP studyInternational Journal of Obesity, 2013
- A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity‐related risk factors (COR‐II)Obesity, 2013
- Effect of Anti-Obesity Drug on Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsPLOS ONE, 2012
- Effects of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight: A Meta-AnalysisExperimental Diabetes Research, 2012
- Controlled‐Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP)Obesity, 2012
- Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutideInternational Journal of Obesity, 2011
- Effectiveness of Medications Used to Attenuate Antipsychotic-Related Weight Gain and Metabolic Abnormalities: A Systematic Review and Meta-AnalysisNeuropsychopharmacology, 2010
- Effects of Exenatide and Lifestyle Modification on Body Weight and Glucose Tolerance in Obese Subjects With and Without Pre-DiabetesDiabetes Care, 2010
- One‐year Weight Losses in the Look AHEAD Study: Factors Associated With SuccessObesity, 2009
- Long term pharmacotherapy for obesity and overweight: updated meta-analysisBMJ, 2007